Trial Profile
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms T2NOW
- Sponsors AstraZeneca; AstraZeneca AB
- 15 Dec 2023 This trial has been completed in Poland.
- 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 06 Oct 2023 Results (of DAPA treatment arm, N=245) assessing the efficacy and safety of DAPA or saxagliptin (SAXA) in children and adolescents with T2D presented at the 59th Annual Meeting of the European Association for the Study of Diabetes